Anita T. Shaffer
Articles
Frontline Treatment of Metastatic NSCLC Depends on Biomarkers and Histology
November 21, 2018
Article
Choosing frontline therapy for patients with metastatic non–small cell lung cancer (NSCLC) who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology, according to Gregory J. Riely, MD, PhD.
Regorafenib Sustains OS Benefit in RESORCE Trial Update
September 26, 2018
Article
Regorafenib (Stivarga) maintained a prolonged overall survival (OS) benefit as second-line therapy for patients with advanced hepatocellular carcinoma (HCC) in a 2-year updated analysis of key findings from the pivotal RESORCE trial.
Four-Drug Chemo Combo Significantly Improves Pancreatic Cancer Survival
July 09, 2018
Article
In a major advance that set a new standard of care for the treatment of patients with resected pancreatic cancer, a modified FOLFIRINOX regimen (mFOLFIRINOX) dramatically improved survival compared with standard gemcitabine as postoperative therapy.
Small Study Finds Risk of Cardiac Events With Adjuvant AI Therapy
December 12, 2016
Article
According to a recent study, postmenopausal women with early-stage breast cancer may be at risk of cardiovascular disease from aromatase inhibitor therapy.
Lung Cancer Survival Improved in Patients Who Used a Web App to Report Symptoms
June 07, 2016
Article
Researchers in France have found that patients with lung cancer who used a web-based app to report and track their symptoms achieved impressive gains in survival compared with individuals who were followed using standard protocols.
Pembrolizumab Reaches 40% Three-Year Survival Rate in Melanoma
May 19, 2016
Article
The 3-year survival rate of patients with advanced melanoma treated with pembrolizumab (Keytruda) has reached 40%, with many responders in remission even after stopping treatment.
Online Calculator Provides Individualized Assessment of DCIS Recurrence Risk
March 31, 2016
Article
A nomogram calculates the risk of ipsilateral breast tumor recurrence after breast-conserving surgery.
Preventing Breast and Ovarian Cancer in Younger Women
March 11, 2016
Article
Bright Pink's Women's Health Provider Education program is designed to address gaps in knowledge of young women's genetic cancer risk.
Daratumumab Combo Safe and Effective in Multiple Myeloma
December 08, 2015
Article
The CD38 monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone proved to be safe and showed an 81% response rate in patients with relapsed or refractory multiple myeloma, according to research presented at the 2015 ASH Annual Meeting.